Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Myelofibrosis - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The "Myelofibrosis - Pipeline Insight, 2026" report provides in-depth analysis into the development landscape for Myelofibrosis, detailing over 50 companies and 55 pipeline drugs. The report features profiles of both clinical and pre-clinical stage drugs, comprehensive therapeutics assessments, and highlights inactive products in the pipeline.
Myelofibrosis is a chronic blood cancer primarily driven by clonal abnormalities in hematopoietic stem cells leading to progressive bone marrow fibrosis. This condition is characterized by decreased blood cell production, anemia, enlarged spleen, and fatigue. Classified as a BCR-ABL1-negative myeloproliferative neoplasm, it can originate independently or transition from conditions like polycythemia vera. A strong association exists with mutations in JAK2, CALR, or MPL, which results in overactive JAK-STAT signaling and cytokine release.
Diagnosis hinges on bone marrow morphology, showcasing megakaryocytic atypia and fibrosis. Blood tests often reveal abnormalities such as anemia and leukocytosis. Molecular testing supports diagnosis, although the absence of mutations does not rule it out. Imaging may assess splenomegaly, aiding in distinguishing primary myelofibrosis from other causes or developments from antecedent conditions.
Treatment strategies are determined by symptom severity, risk level, and transplant eligibility. JAK inhibitors like ruxolitinib are pivotal therapies that reduce spleen size and ameliorate symptoms. Other JAK inhibitors-fedratinib, pacritinib, momelotinib-are employed based on patient-specific factors. Supportive measures may include blood transfusions and medication for anemia. The only curative measure, allogeneic stem cell transplant, is reserved for high-risk cases due to its rigorous nature.
The "Myelofibrosis - Pipeline Insight, 2026" report outlines the current status and future prospects of treatments. It covers commercial and clinical assessments of drugs in development, detailing their mechanisms, studies, approvals, and developmental strategies.
Report Highlights
The R&D landscape for Myelofibrosis is evolving, with new therapies targeting novel mechanisms. Companies are actively exploring opportunities to address the challenges in this domain.
Emerging Drugs
- Ropeginterferon alfa-2b (PharmaEssentia Corporation): A long-acting interferon in Phase III trials, aimed at sustained activation of interferon signaling.
- Roginolisib (iOnctura): An allosteric PI3K? modulator in Phase II, it seeks to reverse tumor-associated immune suppression.
- RVU120 (Ryvu Therapeutics): It targets CDK8 and CDK19, modulating oncogenesis-related pathways, now in Phase II trials.
- PRT12396 (Prelude Therapeutics): A mutant-selective JAK2V617F inhibitor, currently in Phase I trials.
Therapeutic Assessment
The report categorizes pipeline drugs by development phases, routes of administration, and molecule types. It additionally covers collaborative, licensing, and acquisition activities impacting drug development.
Key Insights
- Comprehensive pipeline analysis and therapeutic assessments.
- Unmet needs and the impact of emerging therapies.
Key Players & Products
Leading developers include PharmaEssentia, iOnctura, Ryvu Therapeutics, among others. Noteworthy products in research include Ropeginterferon alfa-2b, Roginolisib, RVU120, and PRT12396.
For further insights, access the detailed Myelofibrosis - Pipeline Insight, 2026 report that delves into the intricacies of emerging treatments and innovative approaches in combating Myelofibrosis.
Key Topics Covered:
Introduction
Executive Summary
Myelofibrosis: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Myelofibrosis- Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Ropeginterferon alfa-2b: PharmaEssentia Corporation
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Roginolisib: iOnctura
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
PRT12396: Prelude Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Inactive Products
- Comparative Analysis
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Myelofibrosis Key Companies
Appendix
List of Tables
Table 1 Total Products for Myelofibrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Myelofibrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
A selection of companies mentioned in this report includes, but is not limited to:
- PharmaEssentia Corporation
- iOnctura
- Prelude Therapeutics
- Cellenkos
- Ajax Therapeutics
- Eilean Therapeutics
- Phoenix Molecular Designs
- Ryvu Therapeutics
- Disc Medicine
- Sumitomo Pharmas
- CERo Therapeutics
- Stemline Therapeutics
- Incyte Corporation
- Takeda
- Syntara Limited
- Opna Bio
- Epigenetix
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- GluBio Therapeutics
- Telios Pharma, Inc.
- Sumitomo Pharma
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/6wkt1t
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
